Latest & greatest articles for metformin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on metformin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on metformin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for metformin

121. [Empagliflozin/metformin: benefit assessment according to õ35a Social Code Book V]

[Empagliflozin/metformin: benefit assessment according to õ35a Social Code Book V] Empagliflozin/Metformin: nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A16-1 [Empagliflozin/metformin: benefit assessment according to §35a Social Code Book V] Empagliflozin/Metformin: nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A16-1 [Empagliflozin/metformin: benefit assessment according to §35a Social Code Book V] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (...) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Empagliflozin/Metformin: nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A16-1. [Empagliflozin/metformin: benefit assessment according to §35a Social Code Book V] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit

2016 Health Technology Assessment (HTA) Database.

122. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register (PubMed)

Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register To investigate the relative safety of various glucose-lowering agents as add-on medication to metformin in type 2 diabetes in an observational study linking five national health registers.Patients with type 2 diabetes who had been on metformin monotherapy and started another agent in addition to metformin were eligible for inclusion (...) treatment was associated with significantly lower risks of CVD, fatal CVD, CHD, fatal CHD and CHF.This nationwide observational study showed that second-line treatment with TZD and DPP-4 inhibitor as add-on medication to metformin were associated with significantly lower risks of mortality and cardiovascular events compared with SU, whereas basal insulin was associated with a higher risk of mortality.© 2016 John Wiley & Sons Ltd.

2016 EvidenceUpdates

123. Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION) (PubMed)

Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION) To compare the efficacy and safety of combination of vildagliptin and metformin therapy with metformin uptitration in Chinese patients with type 2 diabetes (T2DM) inadequately controlled with low-dose metformin.In this 24-week prospective (...) , randomized, multicentre, open-label study, patients with T2DM inadequately controlled with metformin ≤1000 mg daily were divided 1 : 1 : 1 : 1 into four prespecified subgroups based on age and body mass index (BMI). Patients in each subgroup were randomized 5 : 1 to receive either vildagliptin (50 mg twice daily) plus metformin [500 mg twice daily; vildagliptin and low-dose metformin (VLDM) group] or metformin uptitration [1000 mg twice daily; high-dose metformin (HDM) group]. The primary endpoint

2016 EvidenceUpdates

124. Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study. (PubMed)

Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study.  To determine the association between use of sulphonylureas and risk of hypoglycaemia in relation to renal function and sulphonylurea metabolic group compared with use of metformin. Population based cohort study using routinely collected data from general practices in England. Clinical Practice Research Datalink (CPRD) database (...) for age, sex, lifestyle, comorbidity, and drug use. The risk of hypoglycaemia in current users of sulphonylureas only was significantly increased compared with current users of metformin only (adjusted hazard ratio 2.50, 95% confidence interval 2.23 to 2.82). The higher risk in current users of sulphonylureas only was further increased in patients with an estimated glomerular filtration rate of less than 30 mL/min/1.73 m(2) (4.96, 3.76 to 6.55). The risk of hypoglycaemia was also significantly higher

Full Text available with Trip Pro

2016 BMJ

125. Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial (PubMed)

Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial To compare the efficacy and safety of liraglutide versus lixisenatide as add-on to metformin in patients with type 2 diabetes not achieving adequate glycemic control on metformin alone.In this 26-week, randomized, parallel-group, open-label trial, 404 patients were randomized 1:1 to liraglutide 1.8 mg or lixisenatide 20 µg as add-on to metformin. Liraglutide (...) for lixisenatide; P = 0.23). The most common adverse events in both groups were gastrointestinal disorders. Greater increases in pulse, lipase, and amylase were observed with liraglutide. Hypoglycemic episodes were rare and similar between the two treatments.At the dose levels studied, liraglutide was more effective than lixisenatide as add-on to metformin in improving glycemic control. Body weight reductions were similar. Both treatments were well tolerated, with low risk of hypoglycemia and similar

Full Text available with Trip Pro

2016 EvidenceUpdates

126. XIGDUO (dapagliflozin/metformin), antidiabetic - type-2 diabetes

XIGDUO (dapagliflozin/metformin), antidiabetic - type-2 diabetes XIGDUO SUMMARY CT14263

2016 Haute Autorite de sante

127. Metformin as prevention in people taking antipsychotic medication

Metformin as prevention in people taking antipsychotic medication Metformin as prevention in people taking antipsychotic medication – Morsels of Evidence \t\t\t\r\n\t\t\t \t\t\t\r\n\t\t\t Like this: Like Loading... ","author":{"@type":"Person","name":"Michael Tam"},"image":["https:\/\/evidencebasedmedicine.com.au\/wp-content\/uploads\/2016\/06\/whitepills.jpg"]} Toggle search form Toggle navigation Evidence-based medicine for general practitioners Jun 14 2016 Metformin as prevention in people (...) taking antipsychotic medication By in , , , , Journal reference: Zheng W, Li XB, Tang YL, Xiang YQ, Wang CY, de Leon J. Metformin for Weight Gain and Metabolic Abnormalities Associated With Antipsychotic Treatment: Meta-Analysis of Randomized Placebo-Controlled Trials. J Clin Psychopharmacol 2015 Oct;35(5):499-509. Link: Published: October 2015 Evidence cookie says… The effect of metformin on cardiovascular disease in people living without diabetes on long-term antipsychotic medication is unknown

2016 Morsels of Evidence

128. Durable response of glioblastoma to adjuvant therapy consisting of temozolomide and a weekly dose of AMD3100 (plerixafor), a CXCR4 inhibitor, together with lapatinib, metformin and niacinamide (PubMed)

Durable response of glioblastoma to adjuvant therapy consisting of temozolomide and a weekly dose of AMD3100 (plerixafor), a CXCR4 inhibitor, together with lapatinib, metformin and niacinamide Glioblastoma multiforme (GBM) is a CNS (central nervous system) malignancy with a low cure rate. Median time to progression after standard treatment is 7 months and median overall survival is 15 months [1]. Post-treatment vasculogenesis promoted by recruitment of bone marrow derived cells (BMDCs, CD11b

Full Text available with Trip Pro

2016 Oncoscience

129. Efficacy and Safety of Titrated Canagliflozin in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sitagliptin (PubMed)

Efficacy and Safety of Titrated Canagliflozin in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sitagliptin To evaluate the efficacy and safety of titrated canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin and sitagliptin.In this randomized, double-blind study, patients with T2DM (N = 218) on metformin ≥1500 mg/day and sitagliptin 100 mg received canagliflozin 100 mg (...) with placebo (p < 0.001). The overall AE incidence was 39.8 and 44.4% for canagliflozin and placebo, respectively. Canagliflozin was associated with an increased incidence of genital mycotic infections.Titrated canagliflozin significantly improved HbA1c, FPG, body weight and SBP, and was generally well tolerated over 26 weeks in patients with T2DM as add-on to metformin and sitagliptin.© 2016 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.

Full Text available with Trip Pro

2016 EvidenceUpdates

130. Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomised, active comparator clinical trial (PubMed)

Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomised, active comparator clinical trial To compare the efficacy and safety of liraglutide versus sitagliptin as add-on to metformin after 26 weeks of treatment in Chinese patients with type 2 diabetes mellitus (T2DM).This 26-week open-label, active comparator trial (NCT02008682) randomized patients (aged 18-80 years) with T2DM (...) inadequately controlled with metformin [glycated haemoglobin (HbA1c) 7.0-10.0% (53-86 mmol/mol)] 1 : 1 to once-daily subcutaneously administered liraglutide 1.8 mg (n = 184) or once-daily oral sitagliptin 100 mg (n = 184), both as add-on to metformin. The primary endpoint was change in HbA1c from baseline to week 26.Liraglutide was superior to sitagliptin in reducing HbA1c from baseline [8.1% (65 mmol/mol)] to 26 weeks, as evidenced by estimated mean HbA1c change of -1.65% (-18.07 mmol/mol) versus -0.98

Full Text available with Trip Pro

2016 EvidenceUpdates

131. Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis. (PubMed)

Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis. Clinicians and patients need updated evidence on the comparative effectiveness and safety of diabetes medications to make informed treatment choices.To evaluate the comparative effectiveness and safety of monotherapy (thiazolidinediones, metformin, sulfonylureas, dipeptidyl peptidase-4 [DPP-4] inhibitors, sodium-glucose cotransporter 2 [SGLT-2] inhibitors (...) , and glucagon-like peptide-1 [GLP-1] receptor agonists) and selected metformin-based combinations in adults with type 2 diabetes.English-language studies from MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials, indexed from inception through March 2015 (MEDLINE search updated through December 2015).Paired reviewers independently identified 179 trials and 25 observational studies of head-to-head monotherapy or metformin-based combinations.Two reviewers independently assessed study

2016 Annals of Internal Medicine

132. Empagliflozin and metformin (Synjardy)

Empagliflozin and metformin (Synjardy) Empagliflozin and metformin | CADTH.ca Find the information you need Empagliflozin and metformin Empagliflozin and metformin Last Updated: April 4, 2016 Result type: Reports Project Number: SR0489-000 Product Line: Generic Name: Empagliflozin and metformin Brand Name: Synjardy Manufacturer: Boehringer Ingelheim (Canada) Ltd. Indications: Diabetes mellitus (Type 2) Submission Type: New Project Status: Complete Date Recommendation Issued: October 25, 2016

2016 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

133. Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: Systematic review and meta-analysis. (PubMed)

Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: Systematic review and meta-analysis. The purpose of this study was to compare the safety and efficacy of DPP-4 inhibitors versus sulfonylurea as adjunctive second-line therapy in patients with type 2 diabetes mellitus, inadequately controlled with metformin mono-therapy.A systematic review of published randomized controlled trials (RCTs) was performed (...) with sulfonylureas. There were insufficient data to assess a difference in the risk for cardiovascular events.The review shows that, in terms of clinical efficacy, there is no significant difference between DPP4-inhibitors and sulfonylurea when either is added to metformin mono-therapy. In contrast, the safety assessment analysis showed a significant decrease in the risk of hypoglycemic events in patients using DPP4-inhibitors.

2016 Clinical and investigative medicine. Médecine clinique et experimentale

134. The effect of ranolazine on glycemic control in patients with type 2 diabetes treated with either glimepiride or metformin (PubMed)

The effect of ranolazine on glycemic control in patients with type 2 diabetes treated with either glimepiride or metformin To report the results of two phase III trials assessing the efficacy of ranolazine for glycaemic control in patients with type 2 diabetes on metformin or glimepiride background therapy.In two double-blind trials we randomized 431 and 442 patients with type 2 diabetes to ranolazine 1000 mg twice daily versus placebo added to either glimepiride (glimepiride add-on study (...) ) or metformin background therapy (metformin add-on study). Patients receiving ranolazine added to metformin had their metformin dose halved (with the addition of a metformin-matched placebo) relative to the placebo group to correct for a metformin-ranolazine pharmacokinetic interaction. The primary endpoint of the trials was the change from baseline in glycated haemoglobin (HbA1c) at week 24.When added to glimepiride, ranolazine caused a 0.51% least squares mean [95% confidence interval (CI) 0.71, 0.32

2016 EvidenceUpdates

135. Canagliflozin and metformin hydrochloride (TBC)

Canagliflozin and metformin hydrochloride (TBC) Canagliflozin and metformin hydrochloride | CADTH.ca Find the information you need Canagliflozin and metformin hydrochloride Canagliflozin and metformin hydrochloride Last Updated: October 10, 2018 Result type: Reports Project Number: SR0480-000 Product Line: Generic Name: Canagliflozin and metformin hydrochloride Brand Name: Invokamet Manufacturer: Janssen Inc. Indications: Diabetes mellitus, type 2 Submission Type: New Project Status: Complete

2016 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

136. Could Metformin be the First Anti-Aging Drug?

Could Metformin be the First Anti-Aging Drug? Could Metformin be the First Anti-Aging Drug? – Clinical Correlations Search Could Metformin be the First Anti-Aging Drug? February 11, 2016 6 min read By Amy Shen Tang, MD P eer Reviewed “I would pay you if you took it away from me. I’d try to buy it back,” said Irving Kahn, the late Wall Street [1]. Mr. Kahn, who founded Kahn Brothers Group, Inc. with his sons more than 40 years ago, took an active role as chair of his company until his passing (...) colleagues at the Institute for Aging Research are looking to make a cheap, generic, widely used drug—metformin—the first to be Food and Drug Association (FDA)-approved for the indication of aging. Metformin is an oral biguanide antidiabetic medication that has been used for over 50 years. It is commonly prescribed as a first-line treatment for type 2 diabetes mellitus and often in combination with other antidiabetic medications including insulin. Metformin reduces blood glucose levels by preventing

2016 Clinical Correlations

137. Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naive Type 2 Diabetes (PubMed)

Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naive Type 2 Diabetes This study assessed the efficacy/safety of canagliflozin (CANA), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, plus metformin extended-release (MET) initial therapy in drug-naïve type 2 diabetes.This 26-week, double-blind, phase 3 study randomized 1,186 patients to CANA 100 mg (CANA100)/MET, CANA 300 mg (CANA300)/MET, CANA100, CANA300, or MET. Primary end point

Full Text available with Trip Pro

2016 EvidenceUpdates

138. dapagliflozin/metformin hydrochloride (XigDuo)

dapagliflozin/metformin hydrochloride (XigDuo) dapagliflozin/metformin hydrochloride | CADTH.ca Find the information you need dapagliflozin/metformin hydrochloride dapagliflozin/metformin hydrochloride Last Updated: December 1, 2015 Result type: Reports Project Number: SR0468-000 Product Line: Generic Name: dapagliflozin/metformin hydrochloride Brand Name: XigDuo Manufacturer: AstraZeneca Canada Inc. Indications: Diabetes Mellitus, Type 2 Submission Type: New Project Status: Complete Date

2016 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

139. Systematic review with meta analysis: Existing evidence is insufficient to justify metformin or other agents as first-line therapy for type 2 diabetes

Systematic review with meta analysis: Existing evidence is insufficient to justify metformin or other agents as first-line therapy for type 2 diabetes Existing evidence is insufficient to justify metformin or other agents as first-line therapy for type 2 diabetes | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see (...) our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Existing evidence is insufficient to justify metformin or other agents as first-line therapy for type 2 diabetes Article Text

2016 Evidence-Based Medicine (Requires free registration)

140. Systematic review with meta-analysis: Most add-on therapies to metformin have similar effects on HbA1c

Systematic review with meta-analysis: Most add-on therapies to metformin have similar effects on HbA1c Most add-on therapies to metformin have similar effects on HbA1c | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional (...) accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Most add-on therapies to metformin have similar effects on HbA1c Article Text Therapeutics/Prevention Systematic review with meta-analysis Most add-on therapies to metformin have similar effects on HbA1c Thomas Karagiannis 1

2016 Evidence-Based Medicine (Requires free registration)